ExCellThera is an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand blood stem and immune cells for therapeutic use. ExCellThera’s lead technology, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials.
Any inquiries relating to potential investment in ExCellThera can be directed to David Millette, COO & CFO.
In an effort to explore the clinical possibilities of its highly innovative solutions, ExCellThera is pursuing research and development collaborations including platform, product and academic collaborations. If you are interested in partnering with ExCellThera please contact David Millette, COO & CFO.